Supplementary Table 1. Plasma biomarkers at week 4

Biomarker	PV Cohort (N = 28) Median % of BL min, max p-value[a]	ET Cohort (N = 11) Median % of BL min, max
B2M	88.2 62.5, 123.8 p <0.005	92.3 73.3, 136.8
CRP	48.3 6.5, 1783.8 p = 0.070	53.8 3.4, 500.0
Ferritin	90.9 43.4, 231.6	86.1 41.0, 149.0
Haptoglobin	86.5 14.8, 233.3	104.2 21.4, 181.8
ICAM-1	100.0 66.4, 153.3	109.0 63.0, 151.6
IL-12p40	100.0 70.8, 170.2	100.0 68.8, 134.0
IL-1ra	80.8 44.5, 150.8 p = 0.095	94.8 74.6, 151.6
IL-6r	97.0 75.0, 113.6	93.3 44.8, 105.9
MCP-1	117.2 49.5, 315.7 p = 0.024	145.1 92.7, 191.4
MIP-1-beta	93.3 41.9, 282.4	135.5 27.4, 188.1
MPO	47.8 7.3, 158.8 p <0.005	81.4 31.0, 277.1
RANTES	116.7 24.6, 361.4	100.0 66.7, 282.6
TNFR2	92.2 48.2, 141.0 p = 0.055	89.3 53.3, 163.0
VCAM-1	92.7 54.5, 147.4	90.1 74.3, 117.2
VEGF	100.0 36.9, 390.4	122.4 42.5, 164.8

B2M, Beta-2-microglobulin; BL, baseline; CRP, C-reactive protein; ET, essential thrombocythemia; ICAM-1, Intercellular Adhesion Molecule 1; IL-12p40, Interleukin 12 subunit p40; IL-1ra, Interleukin 1 receptor antagonist; IL-6r, Interleukin 6 receptor; MCP-1, Monocyte Chemotactic Protein 1; MIP-1-beta, Macrophage Inflammatory Protein-1 beta; MPO, myeloperoxidase; PV, polycythemia vera; RANTES, T-cell-specific protein RANTES; TNFR2, Tumor Necrosis Factor Receptor 2; VCAM-1, Vascular Cell Adhesion Molecule-1; VEGF, Vascular Endothelial Growth Factor

[a]Nominal p-value reported (Wilcoxon mixed-rank test) for $p < 0.1$ (not reported for ET cohort due to small number of patients). No multiple testing was performed. Relevant inflammatory biomarkers were evaluated and reported. No results reported for the following inflammatory markers due to >40% of samples below LLOQ: EPO, GM-CSF, IFN-gamma, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-1-alpha, IL-2, IL-23, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, MIP-1-alpha, TNF-alpha, TNF-beta.

Supplemental Table 2. Momelotinib plasma concentration by time and dose

	100 mg PV + ET				200 mg PV + ET			
Time (weeks)	**n**	**Median (ng/mL)**	**First quartile (ng/mL)**	**Third quartile (ng/mL)**	**n**	**Median (ng/mL)**	**First quartile (ng/mL)**	**Third quartile (ng/mL)**
2	11	26.8	4.82	98.4	12	30.5	18.6	44.6
4	15	16.4	4.19	155	15	24.3	12.8	57.7
8	12	19.4	5.94	41.9	11	39.5	19.4	82.0
12	9	12.1	3.19	14.6	10	22.4	15.2	144
16	9	22.4	11.5	43.8	11	51.3	22.6	177
20	7	24.1	14.4	27.9	9	36.1	25.2	122
24	8	14.4	3.88	25.7	7	44.3	19.4	249

ET, essential thrombocythemia; PV, polycythemia vera.

Supplemental Table 3. Adverse events by cohort and dose

	PV Cohort			ET Cohort		
	100 mg (N = 14)	**200 mg (N = 14)**	**Total (N = 28)**	**100 mg (N = 5)**	**200 mg (N = 6)**	**Total (N = 11)**
Patients with ≥1 TEAE	12 (85.7)	14 (100.0)	26 (92.9)	5 (100.0)	5 (83.3)	10 (90.9)
Most frequent TEAE[a]						
Headache	5 (35.7)	4 (28.6)	9 (32.1)	1 (20.0)	3 (50.0)	4 (36.4)
Dizziness	0	6 (42.9)	6 (21.4)	0	3 (50.0)	3 (27.3)
Fatigue	2 (14.3)	4 (28.6)	6 (21.4)	0	2 (33.3)	2 (18.2)
Hypertension	3 (21.4)	4 (28.6)	7 (25.0)	0	1 (16.7)	1 (9.1)
Nausea	2 (14.3)	4 (28.6)	6 (21.4)	0	2 (33.3)	2 (18.2)
Diarrhea	2 (14.3)	2 (14.3)	4 (14.3)	1 (20.0)	2 (33.3)	3 (27.3)
Somnolence	4 (28.6)	2 (14.3)	6 (21.4)	0	0	0
Thrombocytosis	1 (7.1)	1 (7.1)	2 (7.1)	1 (20.0)	3 (50.0)	4 (36.4)
Vomiting	1 (7.1)	3 (21.4)	4 (14.3)	0	2 (33.3)	2 (18.2)
Pruritus	2 (14.3)	3 (21.4)	5 (17.9)	0	0	0
Pain in extremity	1 (7.1)	2 (14.3)	3 (10.7)	1 (20.0)	0	1 (9.1)
Dyspnea	2 (14.3)	1 (7.1)	3 (10.7)	0	1 (16.7)	1 (9.1)
Asthenia	1 (7.1)	2 (14.3)	3 (10.7)	0	0	0
Constipation	2 (14.3)	1 (7.1)	3 (10.7)	0	0	0

Data reported as n (%)

[a]Reported by ≥3 patients in any dose group.

TEAE, treatment-emergent adverse event.